MK-7684A + Etoposide and Platinum for 1st line treatment of Small Cell Lung Cancer

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT05224141?term=MK-7684A+%2B+Etoposide+and+Platinum+for+1st+line+treatment+of+Small+Cell+Lung+Cancer&draw=2&rank=1